Cargando…
Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study
BACKGROUND: Bevacizumab provides clinical benefit in multiple solid tumours, but is associated with some increase in bleeding risk. Thrombotic events necessitating therapeutic anticoagulation (TA) are common in cancer. This report describes the safety of concurrent bevacizumab and TA in three large...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049570/ https://www.ncbi.nlm.nih.gov/pubmed/21245868 http://dx.doi.org/10.1038/sj.bjc.6606074 |